Jerusalem Post Asks Why Not Use Ivermectin to Treat at Least Early Onset COVID-19?

Jerusalem Post Asks Why Not Use Ivermectin to Treat at Least Early Onset COVID-19?

The Jerusalem Post’s Maayan Jaffe-Hoffman recently went on the record wondering if COVID-19 be treated with an anti-parasite drug that costs less than $1 a day? According to an elite principal investigator out of Sheba Medical Center in Tel Hashomer, the answer is an absolute yes as ivermectin, used to fight parasites in the third world, can and is used around the world to help treat COVID-19.

Prof. Eli Schwartz was featured previously in TrialSite—the president of the Israeli Society of Parasitology and Tropical Diseases led a randomized, controlled double-blinded trial that started back in May 15, 2020, and ran through the end of January 2021 in a bid to investigate the effectiveness of ivermectin in lowering viral shedding among hospitalized patients with mild-to-moderate COVID-19

An extremely economical drug, over 60 studies have shown positive results, dozens of them randomized controlled studies, while other important case series have many influential researchers considering the use of ivermectin as a low-cost option targeting COVID-19.

Maayan Jaffe-Hoffman recently shared that a peer-reviewed study in the American Journal of Therapeutics&nb...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee